Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
19 May 2016 - 10:00PM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the upcoming presentation of its
final results from the Phase 1 study of its drug candidate,
necuparanib, in patients with metastatic pancreatic cancer. The
poster will be presented at the upcoming American Society of
Clinical Oncology (ASCO) 2016 Annual Meeting.
Poster Presentation Details
Abstract #4117 / Poster #109:
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity
of Necuparanib Combined with nab-Paclitaxel and Gemcitabine in
Patients with Metastatic Pancreatic Cancer: Updated Phase 1
ResultsPresentation Date/Time: Saturday, June 4,
2016; 8:00 a.m. –11:30 a.m. CDTPresenter: Eileen
Mary O’Reilly, MD of David M. Rubenstein Center for Pancreatic
Cancer Research, Memorial Sloan Kettering Cancer Center
About NecuparanibNecuparanib is
a novel oncology drug candidate engineered to have a broad range of
effects on tumor cells. The use of heparins to treat venous
thrombosis in cancer patients has generated numerous reports of
antitumor activity; however, the dose of these products has been
limited by their anticoagulant activity. Leveraging its experience
in deciphering the structure-function relationships of complex
therapeutics, Momenta engineered necuparanib from unfractionated
heparin to have significantly reduced anticoagulant activity while
preserving relevant antitumor properties associated with heparins.
A Phase 2 randomized, double-blind, controlled study to evaluate
the antitumor activity of necuparanib in combination with
nab-paclitaxel (Abraxane®) plus gemcitabine, versus nab-paclitaxel
plus gemcitabine alone, in pancreatic cancer is currently underway.
Necuparanib has received Orphan Drug and Fast Track designations
from the U.S. Food and Drug Administration (FDA) for the treatment
of pancreatic cancer.
About MomentaMomenta Pharmaceuticals is a
biotechnology company specializing in the detailed structural and
functional analysis of complex drugs and is headquartered in
Cambridge, MA. Momenta is applying its technology to the
development of generic versions of complex drugs, biosimilar and
potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for oncology and autoimmune
indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release. The company’s logo, trademarks,
and service marks are the property of Momenta Pharmaceuticals, Inc.
All other trade names, trademarks, or service marks are property of
their respective owners.
Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2024 to May 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From May 2023 to May 2024